Patents by Inventor Chigusa Yoshimura

Chigusa Yoshimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY
    Publication number: 20230287119
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Application
    Filed: April 3, 2023
    Publication date: September 14, 2023
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tohru TAKAHASHI, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
  • Anti-CD3 antibody and molecules comprising the antibody
    Patent number: 11618785
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 4, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tohru Takahashi, Chigusa Yoshimura, Shiho Kozuma, Kensuke Nakamura, Chikako Suzuki, Junya Ichikawa
  • ANTI-SIRPalpha ANTIBODY
    Publication number: 20210155707
    Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.
    Type: Application
    Filed: July 9, 2019
    Publication date: May 27, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takashi MATOZAKI, Mayumi SUE, Kensuke NAKAMURA, Chigusa YOSHIMURA
  • Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
    Patent number: 10881734
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 5, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • MONOCLONAL ANTIBODIES TO HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 2 (HFGFR2) AND METHODS OF USE THEREOF
    Publication number: 20200085946
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Application
    Filed: November 19, 2019
    Publication date: March 19, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa YOSHIMURA, Reimi KAWAIDA, Kokichi HONDA
  • ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY
    Publication number: 20190359712
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tohru TAKAHASHi, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
  • Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
    Patent number: 10478496
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: November 19, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • DETECTION OF FGFR2
    Publication number: 20180133314
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Application
    Filed: April 19, 2016
    Publication date: May 17, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Chigusa YOSHIMURA, Reimi KAWAIDA, Kokichi HONDA
  • Anti-FGFR2 antibodies and methods of use thereof for treating cancer
    Patent number: 9714298
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: July 25, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • Anti-FGFR2 antibodies and pharmaceutical compositions thereof
    Patent number: 9481733
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: November 1, 2016
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • ANTI-FGFR2 ANTIBODY
    Publication number: 20160009820
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 14, 2016
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida
  • ANTI-FGFR2 ANTIBODY
    Publication number: 20150125454
    Abstract: The present invention provides an antibody which binds to a fibroblast growth factor receptor.
    Type: Application
    Filed: April 9, 2013
    Publication date: May 7, 2015
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Chigusa Yoshimura, Toshinori Agatsuma, Atsushi Urano, Takako Kimura, Yumi Matsui, Tatsuji Matsuoka, Jun Hasegawa, Yasuki Kamai, Reimi Kawaida